3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Neurofibromatosis 2
1
Macular Degeneration
1
Interventions
Bevacizumab
6
Everolimus
4
Sirolimus
2
Lapatinib
2
HDAC-42
2
vistusertib
1
temsirolimus
1
neratinib
1
icotinib
1
emvododstat
1
brolucizumab
1
brigatinib
1
aflibercept
1
Vascular Endothelial Growth Factor A
1
Valproic Acid
1
Sunitinib
1
Magnetic Resonance Imaging
1
Immunoglobulin G
1
Exome
1
Endostatins
1
Doxycycline
1
Disulfides
1
Crizotinib
1
Cetuximab
1
Axitinib
1
Aspirin
1
AZD 6244
1
89Zr-bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neurofibromatosis 2
×
brolucizumab
×
CNS
×
Clear all
NCT03710564
2023-01-30
MERLIN
Novartis
Phase 3
Terminated
535 enrolled
14 charts